This study investigates whether calcium citrate or calcium carbonate are the optimal supplement to treat secondary hyperparathyroidism following Roux-en-Y gastric bypass operation. Half of the participants will be randomized to receive calcium citrate, while the other half will receive calcium carbonate. The study will be double blinded.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
38
Tablet manufactured to mimic a calcium carbonate tablet
Department of Enodocrinology and Internal Medicine, Aarhus University Hospital
Aarhus, Denmark
Parathyroid Hormone
Time frame: Change from baseline at 6 weeks and 12 weeks
Se-ion-calcium
Time frame: Change from baseline at 6 weeks and 12 weeks
P-magnesium
Time frame: Change from baseline at 6 weeks and 12 weeks
P-phosphate
Time frame: Change from baseline at 6 weeks and 12 weeks
P-25-OH-vitamin D
Time frame: Change from baseline at 6 weeks and 12 weeks
P-calcitriol
Time frame: Change from baseline at 6 weeks and 12 weeks
P-24,25-(OH)2-vitamin D
Time frame: Change from baseline at 6 weeks and 12 weeks
Vitamin D binding protein
Time frame: Change from baseline at 6 weeks and 12 weeks
Procollagen type 1 N-terminal propeptide (P1NP)
Time frame: Change from baseline at 6 weeks and 12 weeks
P-bone specific alkaline phosphatase
Time frame: Change from baseline at 6 weeks and 12 weeks
Cross-linked C-telopeptide (CTX)
Time frame: Change from baseline at 6 weeks and 12 weeks
24h U-calcium
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Roux-en-Y gastric bypass surgery at least 12 months before study inclusion
Time frame: Change from baseline at 12 weeks
24h U-phosphate
Time frame: Change from baseline at 12 weeks